Related references
Note: Only part of the references are listed.Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist
Rudolph M. Navari
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial
Zhaocai Yu et al.
SUPPORTIVE CARE IN CANCER (2009)
The acute effect of tropisetron on ECG parameters in cancer patients
Ozlem Yavas et al.
SUPPORTIVE CARE IN CANCER (2008)
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
M. S. Aapro et al.
ANNALS OF ONCOLOGY (2006)
Re: The effects of onclansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia
M Aapro et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2005)
The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia
M Buyukavci et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2005)
Increased P-wave dispersion predicts recurrent atrial fibrillation after cardioversion
C Perzanowski et al.
JOURNAL OF ELECTROCARDIOLOGY (2005)
Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study
P Eisenberg et al.
ANNALS OF ONCOLOGY (2004)
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist -: Results of a phase III, single-dose trial versus dolasetron
P Eisenberg et al.
CANCER (2003)
Comment: electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists
AJ Coop
ANNALS OF PHARMACOTHERAPY (2003)
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
R Gralla et al.
ANNALS OF ONCOLOGY (2003)
The cardiotoxic potential of the 5-HT3 receptor antagonist antiemetics: Is there cause for concern?
DL Keefe
ONCOLOGIST (2002)
Share Paper
